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Tumor-Penetrating Delivery of 
siRNA against TNFα to Human 
Vestibular Schwannomas
Yin Ren1,2,3,4, Jessica E. Sagers1,2,5, Lukas D. Landegger1,2,3,6, Sangeeta N. Bhatia4,7,8,9,10 & 
Konstantina M. Stankovic1,2,3,5
Vestibular schwannoma (VS) is the most common tumor of the cerebellopontine angle, and it typically 
presents with sensorineural hearing loss. The genomic landscape of schwannoma is complex and many 
of the molecules implicated in VS pathogenesis represent targets not amenable to antibody-based or 
small molecule therapeutics. Tumor-targeted delivery of small interfering RNA (siRNA) therapeutics 
provides a direct and effective means to interrogate targets while minimizing off-target effects. 
To establish a preclinical model for therapeutic inhibition of putative targets in VS, archived tumor 
specimens, fresh tumor cells derived from patients with sporadic VS, and an established schwannoma 
cell line were screened. Nanoparticles directed by the tumor-homing peptide iRGD were selectively 
taken up by primary VS cultures in vitro via interactions with αvβ3/β5 integrins and neuropilin-1 (NRP-
1). Cellular uptake was inhibited by a neutralizing antibody against αv integrin in a dose-dependent 
manner. When applied to primary VS cultures, iRGD-targeted nanoparticles delivered siRNA directed 
against TNFα in a receptor-specific fashion to potently silence gene expression and protein secretion. 
Taken together, our results provide a proof of principle for tumor-targeted, nanoparticle-mediated 
delivery of siRNA to VS and establish a novel platform for the development and pre-clinical screening of 
molecular therapeutics against VS.
Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle and the fourth most 
common intracranial tumors1. They arise from Schwann cells lining the vestibular branch of cranial nerve VIII 
and are associated with significant morbidity including asymmetric sensorineural hearing loss (SNHL) which 
affects 95% of patients, dizziness, other cranial neuropathies such as facial palsy, and even brainstem compression 
and hydrocephalus2.
To date, the mainstays of therapy for growing VSs include surgical resection and stereotactic radiation, as 
there are currently no FDA-approved systemic medical therapies to treat VS or ameliorate VS-associated SNHL. 
Several clinical trials for neurofibromatosis type 2 (NF2)-associated VSs are ongoing3,4. Targeted molecular 
pharmacotherapy to inhibit the VEGF-A signaling pathway in NF2-associated VS has shown early encouraging 
results; however, substantial side effects such as renal failure prevent widespread clinical use5,6.
Work from our laboratory and others has recently begun to uncover new molecular targets implicated in VS 
tumorigenesis and associated SNHL. For instance, we identified NF-κB as a central regulator in VS proliferation 
and survival, which can be targeted by clinically relevant inhibitors7. We have shown that biological differences 
exist in gene expression and proteomic profile between sporadic VSs associated with SNHL and VSs associated 
with good hearing8,9. Furthermore, there appears to be a correlation between the degree of SNHL in patients with 
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sporadic VSs and the extent of cellular damage when tumor secretions from these patients are applied to murine 
cochlear explants10. Using a candidate molecule approach, we identified tumor necrosis factor alpha (TNFα) as 
an ototoxic molecule11. However, attempts to target the NF-κB pathway or inhibit TNFα secretion using small 
molecules yielded only modest benefits in vitro11.
As more molecular pathways in VS pathogenesis are discovered, one potential therapeutic strategy is to 
directly downregulate mediators of tumor growth or ototoxic effects using small interfering RNAs (siRNAs). RNA 
interference (RNAi) is particularly attractive in addressing gene targets that do not yet have small molecule or 
antibody-based antagonists. Furthermore, RNAi can be easily scaled up for both in vitro screens and pre-clinical 
studies in animal models. Nevertheless, the effective delivery of intact siRNA molecules into the cytoplasm of 
tumor cells remains the biggest barrier for clinical translation of RNAi-based therapies12. Systemically adminis-
tered siRNAs must remain stable in circulation and home to the organ of interest while avoiding accumulation in 
normal tissue. Furthermore, siRNAs must also be selectively taken up by tumor cells, escape endosomal entrap-
ment, and be ultimately incorporated into the RNA-induced silencing complex (RISC) in order to downregulate 
gene expression.
Cancer nanotechnology offers an attractive solution to the delivery problem. Nanoparticles can be engineered 
to protect siRNA from degradation by serum nucleases, and to shield the cargo from clearance mechanisms such 
as the renal glomerular filtration system and the hepatic reticuloendothelial system. Utilizing the enhanced per-
meability and retention (EPR) effect, nanoparticles preferentially accumulate in tumor tissue as a result of hyper-
vascularity and impaired lymphatic drainage in tumors13. By decorating the surface of nanoparticles with affinity 
ligands such as tumor-targeting peptides, siRNA therapeutics can be preferentially directed to tumor cells of 
interest via specific cell surface receptor-ligand interactions. This form of synaphic targeting can further improve 
the micro-distribution of siRNA therapeutics within the tumor by enhancing cellular uptake, retention and sub-
sequent internalization14. This strategy has been successfully employed to deliver siRNA therapeutics across the 
blood-brain barrier (BBB)15,16. More recently, a new class of tumor-penetrating peptides has been discovered, 
which dramatically enhances the targeting of macromolecules and nanoparticles to tumors17. The prototypical 
peptide, iRGD (internalizing RGD, CRGDR/KGPDC), binds to αvβ3/β5 integrins expressed in tumor cells and 
tumor-associated vasculature. Subsequent proteolytic cleavage of iRGD unveils the cryptic C-terminal arginine, 
also known as the CendR domain, which activates a trans-tissue transport pathway by binding to neuropilin-1 
(NRP-1)17–19. This allows infiltration of macromolecular payloads such as albumin-bound paclitaxel and nano-
particles as the tumor becomes more “leaky”20,21. Compared to non-tumor penetrating conventional RGD pep-
tides, iRGD dramatically enhances the accumulation and efficacy of delivered drugs.
Previously, our laboratory has engineered a peptide-based siRNA delivery platform for rapidly credentialing 
gene targets in a mouse model of disseminated ovarian cancer22. The delivery system consists of a tandem peptide 
containing two domains: a nine-amino acid cyclic peptide that is both tumor-targeting and tissue-penetrating, 
and an amphipathic domain which interacts with the cellular membrane to mediate escape from endosomal 
entrapment23. When complexed with siRNA directed against an oncogene essential for tumor growth, nano-
particles penetrated tumor parenchyma and delivered siRNA into the cytoplasm of tumor cells to reduce tumor 
growth and prolong animal survival. We hypothesized that such a peptide-based delivery system could be 
adapted for siRNA delivery to primary human VS cultures and could modulate the secretion of molecules that 
may mediate ototoxicity.
In this study, we report the development of a tandem peptide-based siRNA delivery system to target primary 
human VS cultures in vitro. Peptides bearing a tumor-targeting domain (iRGD) and a membrane-translocation 
domain stably encapsulated siRNAs into nanoparticles. In an NF2-derived cell line and primary human VS cells, 
there was an overexpression of αvβ3/β5 integrins and NRP-1, cognate receptors for the iRGD targeting pep-
tide. Nanoparticles were selectively taken up into the cytoplasm of tumor cells in a receptor-specific fashion. 
Furthermore, nanoparticle-mediated delivery of siRNA directed against TNFα resulted in potent reduction of 
protein levels in VS secretions from tumors associated with SNHL.
Results
Design and characterization of tumor-penetrating nanoparticles. Our goal was to engineer a nan-
oparticle platform that could penetrate the tumor parenchyma, bind selectively to vestibular schwannoma cells, 
and deliver siRNA into the cytoplasm. We began by investigating the ability of nanoparticles consisting of tan-
dem-peptides complexed with siRNA molecules, previously developed in the laboratory to target human epithe-
lial ovarian cancer cells, to target vestibular schwannoma cells. The peptide bearing the N-terminal myristoylated 
acid followed by the cell internalization domain Transportan (TP) and the C-terminal targeting domain iRGD 
(CRGDKGPDC) was chosen for this study (Fig. 1A). Transportan is an amphipathic cell penetrating peptide that 
ubiquitously translocates across the cellular membrane24 and condenses siRNAs into nanoparticles25. The iRGD 
peptide consists of the canonical RGD motif which functions as the affinity ligand for αv integrins, and a cryptic 
C-terminal arginine motif (RGDK), which is unveiled upon proteolytic processing and interacts with NRP-1 
to trigger tissue penetration17,26. Both αv integrins and NRP-1 have been reported to be overexpressed in many 
tumor types in vitro and in vivo, including CNS tumors such as glioblastomas, ependymomas, and vestibular 
schwannomas27. The tandem peptides were admixed with siRNA molecules at a molar ratio of 10:1 (peptide to 
siRNA), as previous studies have suggested that siRNA molecules can be maximally encapsulated by peptides at 
this ratio23. This resulted in stable sub-100nm nanoparticles based on non-covalent charge-based interactions 
between the positively-charged amino acid sequence and the negatively-charged nucleic acid backbone. When 
peptides were mixed with siRNA in pure water or water with 5% dextrose (D5W), the average hydrodynamic 
diameter was determined to be approximately 80 nm (Fig. 1B). When admixing occurred in phosphate-buffered 
saline (PBS) or cell culture medium, the resulting particles showed an increase in apparent size to approximately 
250–300 nm, likely secondary to some degree of aggregation when electrostatic interactions were neutralized28. 
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Control nanoparticles were generated with tandem peptides bearing the non-integrin binding peptide domain 
(scr, CRGEKGPDC), which shared the same number of amino acids and surface charge as iRGD. Both iRGD and 
scr control nanoparticles had similar hydrodynamic size distributions, polydispersity indices between 0.25 and 
0.3, and zeta potentials between +25 to +35 mV (Supplementary Figure 1). To investigate the long-term stability 
of peptide-siRNA complexes, freshly prepared nanoparticles were incubated at room temperature over time. The 
hydrodynamic diameter remained stable after an incubation period of 5 days (Fig. 1C).
Patient Demographics. Primary vestibular schwannoma (VS) cells were derived from tumor specimens 
resected from patients with unilateral, sporadic VS per established protocols29,30. Control healthy nerve specimens 
from surgically sacrificed human great auricular nerves (GANs) were also harvested per established protocols. 
Demographics of the patients used in this study are summarized in Table 1. A combination of patients with good 
hearing in the ipsilateral ear and patients with poor hearing in the ipsilateral ear were selected for the study. 
Compared to patients with good hearing, word recognition scores (WR) were significantly lower and ipsilateral 
pure tone averages (PTA) were significantly greater in patients with poor hearing. In all subjects, the contralateral 
ear did not exhibit significant SNHL.
Cell surface expression of receptors for nanoparticle targeting. To determine the feasibility of nan-
oparticle targeting in VS, the receptor expression profile on the tumor cell surface was assessed. Specifically, αv 
integrin is a part of the family of αvβ3 and αvβ5 integrins which mediates binding of RGD peptide-directed 
nanoparticles17,31. NRP-1 is a receptor for the iRGD peptide, which contains the C-terminal arginine motif 
Figure 1. Characterization of iRGD-targeted nanoparticles. (A) Schematic of iRGD nanoparticle formation. 
Tandem peptides consisting of three domains: N-terminal myristoylated acid, cell penetrating peptide domain 
(Transportan, colored in green), and a cyclic CendR targeting peptide domain (iRGD, CRGDK/RGPDC, 
colored in blue), is non-covalently mixed with siRNA cargo at a molar ratio of 10:1 (peptide to siRNA) to form 
nanoparticles as shown. (B) Dynamic light scattering (DLS) measurements of hydrodynamic diameter of 
nanoparticles in pure water (H2O, black), 5% dextrose in water (D5W, gray), phosphate buffered saline (PBS, 
red), or DMEM cell culture media (Media, blue). Representative histograms from 5 independent preparations 
are shown. (C) The hydrodynamic diameter of nanoparticles does not change significantly after incubating for 
5 days at room temperature. NS, not significant. Error bars represent standard deviation (n = 5 independent 
preparations).
www.nature.com/scientificreports/
4ScIentIfIc RePoRTS | 7: 12922  | DOI:10.1038/s41598-017-13032-9
and functions as a key mediator for tissue extravasation and tumor penetration26. We hypothesized that both 
VS-derived primary cell cultures and archived tumor specimens from patients with unilateral, sporadic VS over-
expressed sufficient amounts of αv integrin and NRP-1. An established human epithelial ovarian cancer cell line 
(OVCAR-8) known to express both receptors was used as a positive control22. In an NF2-derived human schwan-
noma cell line (HEI-193) and in human primary VS cells from 3 different tumors, αv integrin was overexpressed 
on the cell surface as determined by immunofluorescence staining (Fig. 2A–D). Consistent with prior reports, 
integrin expression was mainly observed along the cellular periphery, with clusters of bright aggregations likely 
contributing to the adherence of cells onto the culturing substrate32. Similarly, HEI-193 and human primary 
VS cells from 3 different tumors expressed NRP-1 on the cell surface at a level similar to that of OVCAR-8 cells 
(Fig. 2E–H).
To further confirm the presence of αv integrins and NRP-1 at the cell surface and to quantitatively assess the 
level of expression on a single-cell basis, flow cytometry analyses were performed using polyclonal antibodies 
directed against αvβ3 and NRP-1. IgG antibodies from the same species were used as isotype controls. Significant 
levels of cell-surface αvβ3 and NRP-1 were detected in OVCAR-8 ovarian cancer cells, HEI-193 human vestibular 
schwannoma cells, and human primary VS cells from 4 different tumors (Fig. 3A,B). Interestingly, in comparison 
to immortalized cancer cell lines, primary VS cells freshly harvested from patients exhibited approximately two- 
to three-fold higher levels of receptor expression (Fig. 3C,D).
The in vivo tumor targeting and tissue penetration of iRGD-directed nanoparticles is dependent on the selec-
tive presentation of receptors on the surface of tumor cells relative to surrounding neuronal tissue counterparts. 
To assess the potential for iRGD peptide-siRNA nanoparticles to bind to vestibular schwannoma cells in vivo, 
αv integrin and NRP-1 expression were examined in histological sections of tumors derived from patients with 
sporadic VSs using immunofluorescence. Control healthy nerve sections were prepared from surgically sacri-
ficed healthy human GANs during parotidectomies and neck dissections and used as negative controls. Clusters 
of tumor cells that stained strongly positive for both αv integrin and NRP-1 were found throughout the tumor 
parenchyma (Fig. 4A–D) in 11 different tumors. Certain tumor specimens exhibited higher expression levels 
of both receptors, but this did not correlate with the severity of SNHL in patients (Supplementary Figure 2). By 
contrast, six different GAN control samples demonstrated minimal expression of either receptor (Fig. 4E,F). In 
sum, these results suggest that both primary human VS cultures and an NF2-derived VS cell line overexpress αv 
integrins and NRP-1 on the cell surface, which can be harnessed for receptor-targeted, tumor-penetrating deliv-
ery of therapeutics via the CendR pathway.
Peptide-siRNA nanoparticle targeting of VS in vitro. We next assessed the ability of iRGD-directed 
peptide-siRNA nanoparticles to target vestibular schwannoma cells in a receptor-specific fashion. Nanoparticles 
were prepared by admixing siRNA labeled with a fluorescent dye with the iRGD peptide at a molar ratio of 10:1 
(peptide to siRNA). A tandem peptide bearing the non-integrin binding domain (scr) was used as a negative con-
trol to verify receptor-specificity over non-specific charge-based interactions. Independently prepared targeted 
iRGD and control scr nanoparticles were incubated over OVCAR-8 ovarian cancer cells, HEI-193 NF2-derived 
vestibular schwannoma cells, and human primary VS cells, and siRNA accumulation was assessed using both 
epifluorescence microscopy and flow cytometry. Compared to scr nanoparticles which displayed minimal siRNA 
uptake, uptake of iRGD nanoparticles by HEI-193 cells was 1.6-fold higher than scr controls at 4 °C, and 2.7-fold 
higher at 37 °C, likely due to contributions from the active tumor-penetration pathway (Supplementary Figure 3). 
Furthermore, iRGD targeted nanoparticles were strongly associated with tumor cells (Fig. 5A–C). Established 
cancer cell lines and primary VS cultures displayed different patterns of co-localization of fluorescent siRNAs 
Tumor ID Subject Age Gender
Tumor Size 
(mm)
Ipsilateral Ear Contralateral Ear
PTA (dB) WR (%) PTA (dB) WR (%)
VS-1 36 F 9 40 72 18 98
VS-2 30 F 30 28 92 30 100
VS-3 34 F 8 15 94 5 98
VS-4 63 M 15 72 20 10 100
VS-5 46 F 35 50 10 20 96
VS-6 76 M 20 100 0 10 90
VS-7 36 F 23 8 100 5 100
VS-8 28 F 33 40 18 0 98
VS-9 74 F 27 22 74 5 90
VS-10 52 F 27 15 96 10 94
VS-11 51 M 31 25 100 0 76
VS-12 18 F 35 60 100 15 100
VS-13 40 F 32 100 0 100 0
VS-14 23 F 37 58 63 100 0
Table 1. Demographics of patients selected in the study. Tumor ID, subject age, gender, tumor size (mm, largest 
transverse dimension), pure tone average (PTA, dB), and word recognition score (WR, %) for the ipsilateral and 
contralateral ears to VS are shown.
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with αv integrins. This is likely a result of differences in αv integrin surface expression, where integrin proteins 
localize to cell-cell contact junctions and the cellular periphery in immortalized cells but appear more diffuse in 
primary VS cultures. The punctate pattern of cellular accumulation at 4 °C, where receptor-mediated endocytosis 
pathways were likely inactive, was likely due to the clustered expression profile of αv integrins at the cellular sur-
face. Delivered siRNA molecules tagged with a fluorophore co-localized with αv integrins but not with schwann 
cell marker S100, again suggesting that cellular uptake is mediated via the αv integrin receptor (Supplementary 
Figure 4). Nanoparticle targeting did not significantly affect HEI-193 cell viability in six independent experiments 
(Supplementary Figure 4). The amount of cellular uptake of iRGD-targeted nanoparticles was markedly higher 
than that of control nanoparticles, measuring approximately two-fold in established cell lines and over three-fold 
in human primary VS cells (Fig. 5D, Supplementary Figure 3).
If nanoparticles were indeed delivered in a receptor-dependent manner, the amount of cellular uptake of 
siRNA should be proportional to the dose of the ligand at low concentrations, while saturating at higher ligand 
concentrations as all available receptors become occupied by the ligand. To quantitatively assess the binding affin-
ity of nanoparticles to αv integrins, HEI-193 cells were incubated with varying concentrations of iRGD-targeted 
nanoparticles for one hour, washed, and treated with trypsin to remove any nanoparticles loosely associated 
with the cell surface via non-specific interactions. Intracellular siRNA fluorescence was quantified using flow 
cytometry. At low nanoparticle concentrations, cellular fluorescence was linearly proportional to the amount of 
siRNA present, whereas at higher concentrations, cellular uptake became saturated (Fig. 5E). The apparent bind-
ing affinity as measured by the dissociation constant (Kd) was 41 nM, consistent with values ranging from 17.8 
to 61.7 nM reported in the literature17. To further confirm that uptake of iRGD nanoparticles was specific to the 
interaction between the RGD domain to αv integrins, a blocking antibody against αv was applied to cell culture 
prior to the addition of nanoparticles. Dose-dependent inhibition of siRNA delivery was observed with antibody 
concentrations ranging from 3 to 50 µg/ml, whereas the addition of a control antibody had no effect (Fig. 5F,G).
Tumor-targeted delivery of siRNA to suppress TNFα secretion. Having found that iRGD 
peptide-siRNA nanoparticles could home to VS cells in vitro, we next investigated the ability of nanoparticles 
to mediate the delivery of siRNA directed against genes of therapeutic interest. In patients with VS who also 
have ipsilateral SNHL, there is a positive correlation between the degree of SNHL and the amount of TNFα 
present in VS secretions. Application of TNFα-containing VS secretions onto murine cochlear explant cultures 
results in the loss and disorganization of neurites, and neutralization of TNFα partially rescued both inner 
and outer hair cell loss11. We assessed whether iRGD-targeted nanoparticles could achieve functional deliv-
ery of siRNA against TNFα to VS cells in a receptor-specific fashion. Again, nanoparticles were prepared by 
Figure 2. Expression of surface receptors in tumor cell lines and primary human vestibular schwannoma (VS) 
cultures for iRGD nanoparticle targeting. (A–D) Immunofluorescence staining of αv integrin (pseudocolored 
red) in OVCAR-8 cells (A), an ovarian cancer cell line known to express αv integrins on the cell surface; HEI-
193 cells (B), a neurofibromatosis type 2 vestibular schwannoma cell line; and primary human VS culture (C 
and D) where (D) is an enlarged section from dashed rectangle of (C). Nuclei are counterstained with DAPI 
(pseudocolored blue). For established cell lines, representative images based on 6 independent experiments are 
shown. For VS cultures, representative images from 3 biological replicates from different tumors are shown. (E–
H) Immunofluorescence staining of Neuropilin-1 (NRP-1, pseudocolored green) in OVCAR-8 cells (E), HEI-
193 cells (F), and primary human VS culture (G and H) where (H) is an enlarged section from dashed rectangle 
of (G). Nuclei are counterstained with DAPI (pseudocolored blue). Six (6) independent experiments were 
performed for established cell lines, whereas 3 different tumors were analyzed. All scale bars are 100 µm.
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incubating tandem peptides bearing the pendant iRGD targeting domain with a mixture of siRNA sequences 
targeting non-overlapping exons of TNFα mRNA, whereas tandem peptides bearing the scr domain mixed with 
the same siRNAs were used as negative controls. Furthermore, to control for gene silencing effects that were 
not sequence-specific, siRNA directed against the non-human green fluorescent protein (GFP) gene was used. 
Various formulations of independently prepared nanoparticles were incubated over HEI-193 cells for 4 hours, 
and cells were harvested 48 hours later for gene expression analysis by qRT-PCR (N = 6 independent replicates 
per condition). Compared to cells treated with media alone, scr control nanoparticles carrying siTNFα, or iRGD 
nanoparticles carrying siGFP, delivery of TNFα-specific siRNA by iRGD-targeted nanoparticles resulted in a 
modest but significant suppression of TNFα gene expression by over 50%. By contrast, there was no statistical 
Figure 3. Expression of αv integrins and NRP-1 in cell lines and primary VS cultures as determined by flow 
cytometry. (A) Flow cytometry analysis of αvβ3 integrin expression in OVCAR-8 (left panel), HEI-193 (center 
panel), and human VS cultures (right panel). Red, αvβ3 integrin antibody. Black, IgG isotype control. Shaded 
histogram represents unstained OVCAR-8 or HEI-193 cells. Representative histograms from six independent 
replicates are shown. (B) Flow cytometry analysis of NRP-1 surface expression. Red, NRP-1 antibody. Black, 
IgG isotype control. Shaded represents unstained OVCAR-8 or HEI-193 cells. Representative histograms from 
six independent replicates are shown. (C) Quantification of αvβ3 integrin expression in cell lines and human 
VS cultures. Red bars, anti-αvβ3 antibody; black bars, IgG control antibody. Error bars represent standard 
deviation. (n = 6 independent replicates for cell lines, 4 different tumors for VS cultures). (D) Quantification 
of NRP-1 expression. Green bars, anti-NRP-1 antibody; black bars, IgG control antibody. Error bars represent 
standard deviation. (n = 6 independent replicates for cell lines, 4 different tumors for VS cultures).
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difference in TNFα gene expression between the three negative control conditions (Fig. 6A). As a positive control, 
transfection of siTNFα using a commercially available cationic lipid-based reagent (Lipofectamine RNAiMAX®) 
achieved approximately 40% gene silencing, which is slightly less potent than our nanoparticle formulation but 
does not reach statistical significance (Fig. 6A).
Inhibition of TNFα secretion in response to pro-inflammatory stimulus. TNFα is a key cytokine 
produced by multiple cell types in the central nervous system in response to foreign pathogens to orchestrate an 
inflammatory response in many disease processes, including SNHL33. Therefore, we envisioned that an effective 
therapeutic strategy for VS should blunt the inflammatory signaling cascade by inhibiting the secretion of TNFα 
when cells are exposed to a pro-inflammatory stimulus. To investigate the efficacy of nanoparticle-mediated 
siRNA delivery, HEI-193 cells were treated with nanoparticles loaded with TNFα-specific siRNA, followed 
immediately by treatment with lipopolysaccharide (LPS), a known inducer of multiple cytokines as part of 
the inflammatory pathway34. All cells were treated with either medium alone or various nanoparticle formu-
lations, followed by exposure to LPS prior to RNA collection (N = 6 independent experiments). Compared 
to medium-treated cells, treatment with scr control nanoparticles did not suppress TNFα gene expression in 
response to LPS. However, TNFα expression was significantly downregulated when siRNA against TNFα was 
introduced to the cells by either lipofectamine transfection reagent or iRGD-targeted nanoparticles. While there 
is a modest difference between iRGD nanoparticle treatment with siGFP versus siTNFα, this does not reach sta-
tistical significance (Fig. 6B).
Having established that iRGD-targeted delivery of siRNA can lead to receptor- and sequence-specific suppres-
sion of TNFα gene expression in an NF2-derived vestibular schwannoma cell line, we then evaluated the ability of 
iRGD nanoparticles to mediate RNAi in primary human VS cultures. Nanoparticles were again synthesized with 
either iRGD tandem peptides or scr tandem peptides admixed with respective siRNA cargoes. Both formulations 
were confirmed to exhibit similar physiochemical properties including size distributions, polydispersity, and zeta 
potential (Supplementary Figure 1). Nanoparticles bearing the pendant iRGD domain and siTNFα were applied 
to primary VS cultures derived from patients who also had significant ipsilateral SNHL (N = 4–6 independent 
tumors). After incubation with nanoparticles for 4 hours, the cells were washed and further incubated for 48 
hours. Lipopolysaccharide was then added as an immunostimulatory input before tumors were harvested and 
tumor secretions ultimately collected for TNFα measurements 18 hours later. The relative gene expression of 
TNFα was normalized to cells that received medium alone prior to LPS exposure. VS cultures exposed to iRGD 
nanoparticles with TNFα-specific siRNA resulted in over 90% reduction in TNFα mRNA expression (Fig. 6C). 
This was statistically significant when compared to all other control conditions as well as lipofectamine treatment. 
Figure 4. Expression of receptors for iRGD targeting in human VS specimens and healthy nerve controls. 
Immunofluorescence images of formalin-fixed, paraffin-embedded histological sections of human vestibular 
schwannomas (A–D) and great auricular nerve (GAN) controls (E,F). Top row, green represents αv integrin 
expression. Cell nuclei are counterstained with DAPI (pseudocolored blue). Scale bar, 100 μm. Bottom 
row, green represents NRP-1, blue represents DAPI nuclear stain. Scale bar, 100 μm. Representative 20x 
magnification images from 6–9 histological sections per specimen are shown. Specimens from 11 different VSs 
and 6 different GAN were analyzed.
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Figure 5. Receptor-specific targeting of iRGD nanoparticles in cancer cell lines and primary human 
vestibular schwannoma cells. (A–C) Representative immunocytochemistry images of nanoparticle uptake in 
OVCAR-8 cells (A, based on 6 different experiments), HEI-193 cells (B, based on 6 different experiments), 
and human vestibular schwannoma cells (C, based on 4 biological replicates from different patients) in vitro. 
Red, αv integrin. Green, nanoparticle (NP) with siRNA labeled with a fluorescent dye (Alexa Fluor 647). 
Blue, DAPI nuclear stain. Yellow pseudocolor suggests co-localization between siRNAs and αv integrin 
receptors. Scale bar, 100 μm. (D) Quantification of cellular uptake of iRGD targeted nanoparticles (iRGD, 
black bars) versus control nanoparticles (scr, gray bars) in OVCAR-8 cells, HEI-193 cells, and human VS 
cultures. Error bars represent standard deviation. N = 4–6 independent replicates. *P < 0.05, **P <0.01, 
Student’s two-tailed t-test. (E) Dose-dependence of nanoparticle binding in HEI-193 cells as determined by 
flow cytometry. Calculated Kd is approximately 41 nM from the binding curve. (F) HEI-193 cellular uptake 
of iRGD-targeted nanoparticles is inhibited by an antibody directed against αv integrin (blue bars) in a 
dose-dependent manner. A control antibody, IgG (gray bars) had no significant effect. N = 6 independent 
replicates. *P < 0.05, Student’s two-tailed t-test. (G) Representative flow cytometry histograms of cellular 
uptake of fluorescently-labeled siRNA in the presence of a blocking anti-αv integrin antibody (blue), control 
IgG (brown), or culture medium (red).
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Figure 6. iRGD nanoparticles mediate TNF-α silencing by RNAi in vitro. (A) Nanoparticle delivery of TNFα 
siRNA to HEI-193 vestibular schwannoma cells. Relative TNFα gene expression quantified by qRT-PCR in cells 
treated with various formulations, in the absence of lipopolysaccharide (LPS) stimulation. Medium, untreated 
controls. siTNFa / scr, control nanoparticles carrying TNFα siRNA. siGFP / iRGD, iRGD nanoparticles 
carrying GFP siRNA. siTNFα / Lipofect, Lipofectamine RNAiMAX® complexed with TNFα siRNA as a 
positive transfection control. siTNFα / iRGD, iRGD nanoparticles carrying TNFα siRNA. Error bars represent 
standard deviation. N = 6 biological replicates with independently prepared nanoparticles. ***P < 0.001, one-
way ANOVA. NS, not significant. (B) Delivery of TNFα siRNA to HEI-193 cells after LPS stimulation. After 
treatment with respective nanoparticle formulations, cells were then exposed to LPS (5 ng/mL) for 18 hours 
to stimulate TNFα production prior to harvesting and isolation of total RNA. Error bars represent standard 
deviation. N = 6 independent replicates. *P < 0.05, one-way ANOVA. NS, not significant. (C) Nanoparticle-
mediated delivery of TNFα siRNA to primary human vestibular schwannomas. Relative TNFα mRNA levels 
were determined by qRT-PCR. Cells were treated with siRNA (100 nM) delivered by various formulations for 
4 hours, further incubated for 48 hours, and stimulated with LPS at 5 ng/ml for 18 hours prior to harvesting. 
Error bars represent standard deviation. Pooled data from 4–6 different tumors are shown. NS, not significant. 
*P < 0.05, ***P < 0.001, one-way ANOVA. (D) Secreted TNFα levels from human VS after nanoparticle 
treatment as measured by ELISA. Error bars represent standard deviation. Pooled data from 4–6 different 
tumors are shown. NS, not significant. *P < 0.05, one-way ANOVA.
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Cells treated with untargeted scr nanoparticles carrying siTNFα demonstrated a mild decrease in TNFα expres-
sion when compared to medium alone, likely a reflection of siRNA uptake independent of the iRGD-αv integrin 
interaction. However, this difference did not reach statistical significance. VS cultures treated with iRGD nano-
particles carrying GFP-targeting siRNA did not show any appreciable reduction in TNFα expression, suggesting 
that gene silencing is sequence-specific. Finally, as a positive control, lipofectamine treatment led to approxi-
mately 50% reduction of TNFα mRNA, a less potent response than that induced by iRGD nanoparticles (Fig. 6C).
Because TNFα protein is the ultimate mediator of ex vivo cellular damage in murine cochlear explants11, we 
explored the ability of tandem peptide-siRNA complexes to suppress TNFα secretion after LPS challenge in VS 
cultures by a series of ELISAs (Fig. 6D). Primary human VSs obtained from patients with ipsilateral SNHL and 
high basal levels of tumor-secreted TNFα were selected for this study (N = 4–6 different tumors). After appli-
cation of LPS, the mean level of TNFα in tumor secretions was between 200 to 300 pg/mL, similar to serum 
levels in patients with inflammatory conditions such as rheumatoid arthritis where high circulating TNFα levels 
were found35. Treatment with siTNFα bound to untargeted nanoparticles, GFP-specific siRNA in iRGD-targeted 
nanoparticles, or siTNFα mixed with a commercial transfection reagent did not lead to appreciable suppression 
of TNFα secretion (range, 360–396 pg/mL). By contrast, tumor-targeted delivery of siTNFα by iRGD tandem 
peptides resulted in a reduction of TNFα levels by approximately 67% to a mean level of 93 pg/mL, which was sta-
tistically significant when compared with both scr control nanoparticles carrying siTNFα and with lipofectamine 
as positive control. Collectively, these experiments show that delivery of siRNA therapeutics guided by the affinity 
interactions between the tumor-homing peptide iRGD and cell-surface αv integrins and neuropilin-1 resulted in 
potent suppression of TNFα secretion in a receptor-specific fashion.
Finally, to test the versatility and generalizability of the nanoparticle delivery system, VS cultures were treated 
with iRGD nanoparticles carrying siRNA directed against RELA, a component of the NF-κB canonical pathway 
implicated in VS growth and a potential therapeutic target7. Delivery of siRNA against RELA by iRGD nanopar-
ticles resulted in significant suppression of NF-κB1 expression, when compared to delivery of GFP siRNA using 
the same nanoparticles (Supplementary Figure 5).
Discussion
We demonstrate for the first time that RNA interference and tumor-targeting nanotechnology can be leveraged 
in a synergistic fashion to deliver siRNA therapeutics to human vestibular schwannoma cells. We focus on ther-
apeutic silencing of TNFα because of its important role as a master regulator cytokine in multiple inflammatory 
responses and downstream signaling pathways, including autoimmune inner ear disease36,37. In addition, we have 
previously shown that VS secretion of TNFα correlates with the severity of VS-induced hearing loss11. The iden-
tification of secreted factors responsible for mediating hearing loss (in addition to mechanical compression of 
the auditory nerve by adjacent tumor tissue and associated edema) motivates the development and validation 
of targeted molecular medicines, which can either be used alone or in conjunction with surgical resection and 
radiation therapy. Unfortunately, to date, no FDA-approved medicinal therapies exist to ameliorate or prevent 
VS-associated hearing loss. While monoclonal antibodies against TNFα, including Infliximab, have been used 
to treat autoimmune conditions such as rheumatoid arthritis, TNF-specific immunotherapies have not been 
deployed in VS. Moreover, the prohibitive cost of antibody development and associated autoimmunity necessi-
tate alternative approaches.
RNAi offers an attractive approach to the perturbation and interrogation of gene targets at the mRNA level. 
Short interfering RNAs (siRNAs) belong to a promising class of therapeutics that could silence gene expression 
with high potency, specificity, and minimal side effects. In theory, RNAi can act on any gene including those 
not targetable by antibodies or small molecules, and is easily scalable for high-throughput screens or clinical 
trials. The translation of RNAi into clinical therapeutics is largely hindered by the challenge of systemic delivery 
of siRNA molecules12. When administered systemically, naked nucleic acid molecules are rapidly cleared from 
circulation by renal filtration. The small amount remaining in circulation is subsequently further degraded by 
serum nucleases. Even when siRNA is directly injected into a tumor, the negatively charged backbones prevent 
these molecules from crossing cellular membranes to reach the cytoplasm and engage in RISC. Delivery of siRNA 
against TNFα has previously been accomplished via direct intra-articular injection38, intravenous administration 
using liposomes or polymeric nanoparticles towards specialized cell populations in mouse models of arthritis39,40, 
and intra-oral delivery to sites of inflammation in the gastrointestinal tract for treatment of inflammatory bowel 
disease41,42. However, none of these approaches have been utilized to target tumor cell populations and cannot be 
generalized across disease models or tissue types.
Achieving targeted delivery of nanoparticle therapeutics to tumors has broad implications in realizing the 
full clinical potential of RNAi. Tumor cells and tumor-associated vasculature express unique receptors on the 
cell surface owing to alterations in signaling and survival pathways. Ligands such as nucleic acids43, aptamers44, 
and peptides45,46, which selectively bind to these receptors with high affinity have been harnessed to improve 
the cellular binding, retention, and overall efficacy of delivered compounds including siRNAs. Nevertheless, the 
therapeutic efficacy of macromolecular therapeutics is largely limited by their poor extravascular transport and 
limited tissue penetration47. This is likely due to a combination of abnormal blood vessels supplying the tumor, 
poor tissue perfusion, and high interstitial pressure due to dysfunctional tumor lymphatics48,49.
The targeting nanoparticle system described here offers several important advances over previously reported 
strategies. First, our system leverages a new class of peptides with both tumor-homing and tissue-penetrating 
properties. Peptides such as iRGD contain the C-terminal exposure of the C-end rule (CendR) motif (R/
KXXR/K), which activates a distinct vascular transcytosis pathway to enhance the entry of macromolecular 
therapeutics including antibodies and nanoparticles20,21. The peptide selectively binds to integrins on vestibular 
schwannoma cells via the RGD sequence, undergoes proteolytic processing and interacts with NRP-1 via the 
CendR motif to trigger cellular internalization and tissue penetration. Both αv integrins and neuropilin-1 are 
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overexpressed in numerous types of tumor tissues in vivo, including those of the central nervous system. Second, 
the tumor-targeting probe utilized here binds to its cognate receptor at high nanomolar affinity, whereas previous 
approaches to suppress TNF have relied on localized, lower-affinity enzymatic activity or microenvironment cues, 
which can be highly variable42. By contrast, the dissociation constant of monomeric iRGD peptide to cells bearing 
αv integrins is likely in the μM range, similar to that of monomeric cyclic RGD given that both peptides engage 
the same cell surface receptor50. This avidity, enhanced by approximately 20-fold, is likely due to the multivalent 
ligand presentation on the nanoparticle surface, thereby further reducing the off rate (Koff)50,51. Third, our system 
is based on a “mix-and-match” paradigm, which does not require custom modification of siRNA or covalent 
linkage to the carrier, and is therefore readily adaptable to address other candidate genes identified from genomic 
screens of human schwannomas52,53.
The compendium of molecular markers expressed uniquely by tumor cells and tumor vasculature that can 
be utilized for targeting has seen an exponential expansion, owing to advances in screening technologies such as 
in vivo phage-displayed screens54 and gene expression profiling55, as well as an improved understanding of the 
pathophysiology of tumorigenesis and angiogenesis56. Correspondingly, there has been a growth in the arsenal 
of tumor-homing peptides to address the rising number of targets. Focusing on delivery strategies for diseases 
of the central nervous system, targeting of siRNA to glioma cells and neurons has been achieved using tandem 
peptides decorated with a transferrin-receptor targeting domain in vitro25, and with peptides derived from rabies 
virus glycoprotein in a mouse model of traumatic brain injury57. However, neither approach enables penetration 
of tissue to target parenchymal tumor cells. Oncolytic recombinant herpes simplex virus (HSV) has been used 
to reduce tumor growth in mouse models of neurofibromatosis, but this viral vector cannot be easily modified to 
target specific receptors or address multiple gene targets58.
The nanoparticle siRNA delivery system described here has the potential to succeed in multiple areas of clin-
ical translation. First, RNA interference is a powerful therapeutic tool to modulate gene expression that can be 
achieved without viral integration. Multiple clinical trials involving non-viral mediated delivery of siRNA are 
underway. The RNAi delivery strategy proposed here is easily scalable and readily adaptable for clinical testing. 
Second, unlike genes essential for tumor growth or survival for which expression is constitutively upregulated, 
the expression of TNFα may be more transient and associated with inflammatory stimuli. Therefore, the transient 
suppression of TNFα expression by RNAi may be more desirable when aiming to prevent hearing loss secondary 
to ototoxic secretions from vestibular schwannomas or other autoimmune etiologies. Third, our delivery system is 
modular and can be modified to test other genes of interest or gene combinations. As more promising targets for 
human vestibular schwannomas emerge, this delivery platform is poised to provide an efficient method to rapidly 
validate new candidate genes in primary culture systems.
The VEGF signaling axis has been implicated in orchestrating SNHL in patients with VS via mechanisms that 
are yet to be fully elucidated. Treatment with a VEGF monoclonal antibody has resulted in hearing improvement 
in patients with NF2-associated VS6, and delivery of siRNA against VEGF or HIF-1α to downregulate VEGF 
expression reduced glioma growth59. Earlier work from our laboratory has identified the transcription factor 
nuclear factor-kappa B (NF-κB) as a key modulator of primary VS survival, and inhibition of NF-κB by small 
molecules or RNAi led to reduction in cell proliferation7. Recently, an integrative analysis of the schwannoma 
genome has been completed to identify common genomic aberrations. Using a combination of whole-exome 
sequencing, methylation profiling and RNA sequencing, a new fusion protein that promotes tumorigenesis via 
the MEK-ERK signaling was found to be present in 10% of schwannomas60. As more promising targets begin 
to emerge from large-scale genomic studies, the current delivery platform can be easily adapted to perturb the 
expression of candidate genes in primary human VS cultures and identify those with potential to serve as thera-
peutic targets.
The group of subjects in this study slightly favored female patients. The role of demographic factors such 
as gender and age in affecting receptor expression or tumor secretions in VS has not been studied in the past. 
Nevertheless, some previous studies have suggested female patients may have smaller tumors and a slightly 
decreased incidence of hearing loss compared to males61. Thus, the receptor expression profile may be influenced 
by subjects’ gender. Further work is needed to probe demographic factors and their effects on the underlying VS 
tumor biology.
Looking forward, our goal is to establish a pipeline that bridges target discovery to preclinical ex vivo and 
in vivo validation in VS. Future studies will involve testing the efficacy and toxicity of the delivery system in 
xenograft and transgenic models of vestibular schwannoma. Since the delivery system is composed of modular 
components, simultaneous suppression of multiple gene candidates targeting distinct survival pathways can also 
be considered. Encouragingly, similar tandem-peptide based delivery technologies have been deployed in mouse 
models of brain injury with minimal toxicity57.
In summary, this work introduces a new approach that leverages tumor-targeting nanoparticles to improve 
the delivery of siRNA to vestibular schwannomas. Primary human VSs and an established schwannoma cell line 
both express αv integrins and neuropilin-1 on the cell surface, two receptors that serve as “zip codes” for the tar-
geting peptide ligand iRGD. We identified a formulation of siRNA-carrying nanoparticles which home to VS in 
a receptor-specific manner and suppressed the pro-inflammatory ototoxic response as evidenced by reduction in 
TNFα secretion. As more genomic targets emerge, our delivery platform can be easily adapted to validate those 
genes, thereby providing a paradigm combining RNA interference and nanotechnology for preclinical validation 
of new therapies for vestibular schwannomas.
Methods
Study population and human specimen collection. Freshly harvested human VS tumor specimens 
from patients with sporadic VS and control great auricular nerve (GAN) were collected from indicated surgeries 
and transported to the laboratory in saline on ice, as is routine in our laboratory11. Informed consent was obtained 
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from all patients. All study protocols were approved by the Human Studies Committee of Massachusetts General 
Hospital and Massachusetts Eye and Ear Infirmary, and conducted in accordance with the Helsinki Declaration. 
The human vestibular schwannoma cell line HEI-193, derived from a patient with neurofibromatosis type 2 
(NF2), was obtained from Dr. Giovanni at the House Ear Institute.
For annotation of the patient population data, variables were defined using previously established criteria. 
These included: age (defined at the time of diagnosis), tumor size (largest diameter parallel to the petrous face), 
pure tone average (PTA; the average of the two lowest hearing thresholds in dB hearing loss measured at frequen-
cies ranging among 0.5, 1, and 2 kHz) and word recognition (WR; the percentage of spoken words a subject can 
discern). Audiometric data were obtained from the latest measurements prior to tumor resection surgery. A PTA 
of 100 dB and WR score of 0% were assigned to a deaf ear.
Nanoparticle synthesis. Details of peptide and siRNA synthesis and nanoparticle formulation have been 
described previously22,23. Briefly, peptides were synthesized via standard FMOC solid-phase synthesis and purified 
by HPLC at the MIT Biopolymers Core or CPC Scientific, Inc. The peptide sequences were: myristoyl-TP-iRGD, 
which targets αv integrins, CH3(CH)13GWTLNSAGYLLGKINLKALAALAKKILGGGGKCRGDKGPDC 
(Cys-Cys di-sulfide bridge, the CendR sequence is shown in italics); and myristoyl-TP-iRGE, a scrambled pep-
tide control, CH3(CH)13GWTLNSAGYLLGKINLKALAALAKKILGGGGK CRGEKGPDC (Cys-Cys disulfide 
bridge). The purity of the peptides was confirmed by HPLC. All siRNAs were synthesized by Dharmacon (GE 
Healthcare) with ON-TARGETplus® siRNA design modifications to minimize off-target effects. The sequences 
of siRNAs were as follows (5′-3′, sense strand without overhangs): siGFP (GGCUACGUCCAGGAGCGCA), 
siTNFα_1 (GACAACCAACUAGUGGUGC), siTNFα_2 (GCAUGGAUCUCAAAGACAA) and siRELA 
(GGAUUGAGGAGAAACGUAA). The purity and concentration of siRNAs were confirmed with 
UV-spectrophotometry (NanoDrop) using absorbances at 260 nm and 280 nm. For nanoparticle synthesis, an 
equal volume of tandem peptide and siRNA stock aliquots prepared at 10x of the final nanoparticle concentration 
were used. Peptide (either iRGD or scr control) was diluted in nuclease-free ddH2O to a molar concentration 
that is 10-fold to that of siRNA, which was also diluted in nuclease-free ddH2O simultaneously. The two equal 
volumes of peptide and siRNA were admixed rapidly and allowed to form nanoparticles over 10 minutes at room 
temperature. The nanoparticle stock solution was then further diluted 10-fold by adding 9-part Opti-MEM (Life 
Technologies) to 1-part nanoparticle solution. The resulting nanoparticles at the desired concentration was then 
used for subsequent experiments.
Dynamic light scattering (DLS) and zeta potential measurements. Nanoparticles were prepared 
by aliquoting equal volumes (10 μL) of either tandem peptide (iRGD or scr control, 50 μM) with siGFP (5 μM) in 
nuclease-free ddH2O at a molar ratio of 10:1 (peptide-to-siRNA) for 10 minutes at room temperature, resulting 
in a total volume of 20 μL. This nanoparticle stock solution was then further diluted in 80 μL of either ddH2O, 5% 
dextrose water (D5W), PBS, or Opti-MEM. For zeta potential measurements, nanoparticles were again formu-
lated as above for a final siRNA concentration of 1 μM in 55 μL of PBS (pH 7.4) and then diluted to 800 μL with 
nuclease-free ddH2O. The hydrodynamic radii and zeta potential were determined using the ZetaSizer-Nano 
ZS90 instrument (Malvern). The mean particle diameter was calculated by the manufacturer’s software from the 
measured particle distributions.
For nanoparticle stability experiments, nanoparticles were allowed to form at room temperature as described 
and subsequently diluted in water, and left incubated at room temperature for 5 days prior to DLS measurement. 
For each zeta potential and diameter measurement, n = 5 independent preparations and characterizations were 
performed.
Cell culture. Details on primary vestibular schwannoma and human Schwann cell cultures have been 
described previously29,30. Briefly, freshly harvested VS or GAN specimen was rinsed in phosphate buffered saline 
(PBS), dissected in culture medium consisting of Dulbecco’s Modified Eagle’s medium (DMEM) with Hams’ F12 
mixture, 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin (Pen/Strep) and 1% Glutamax, all from Life 
Technologies. The primary VS and GAN cultures were maintained for 2 to 4 weeks as previously described29,30. 
Human ovarian cancer cell line OVCAR-8 was cultured in RPMI 1640 medium (Invitrogen) with 10% FBS, 2 mM 
glutamine, and 1% Pen/Strep. Human schwannoma cell line HEI-193 was cultured in DMEM with 10% FBS, 2 
mM glutamine, and 1% Pen/Strep (Invitrogen).
Antibody staining and immunofluorescence imaging. Imaging of surface expression of receptors was 
performed using immunocytochemistry for cell lines and primary VS cultures, and using immunohistochemistry 
for formalin-fixed paraffin-embedded (FFPE) tumor sections. For immunocytochemistry, live cells were rinsed in 
PBS, fixed in 4% paraformaldehyde (PFA) in PBS for 15 minutes, washed twice in PBS, and incubated in blocking 
buffer (10% goat serum, 1% BSA in PBS) for one hour. To stain for only receptors at the cell surface, the cells were 
not permeabilized after fixation. The cells were washed in PBS and incubated with primary antibodies against αv 
integrin (BioLegend, 10 μg/mL), neuropilin-1 (NRP-1, Novus Biologicals, 10 μg/mL), or S100 (Dako) diluted in 
0.1% BSA in PBS overnight at 4°C. The cells were then washed in PBS three times, incubated with respective sec-
ondary antibodies (Alexa 488 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit, Invitrogen, 1:500) for one hour 
at room temperature, washed in PBS, and counterstained with DAPI (Invitrogen) for 5 minutes, and mounted 
onto glass slides using Fluoromount G (Thermo Fisher). The edges of the coverslips were sealed with clear nail 
polish (Electron Microscopy Sciences). Images were obtained on the Nikon Ti-Eclipse TE200 inverted fluores-
cence microscope and NIS Elements Software (Nikon), and analyzed using ImageJ (NIH). A total of 6 biological 
replicates for each cell line and 3 primary VS cultures from different tumors were used for each immunostaining 
experiment.
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For immunostaining of FFPE tumor specimens, human VS were fixed in 4% PFA and embedded in par-
affin, sectioned, deparaffinized with xylene, underwent antigen-retrieval, and blocked in normal horse serum 
(5% NHS, 0.1% Tween-20 in PBS). The sections were incubated with primary antibodies against αv integrin or 
neuropilin-1, followed by corresponding fluorescent secondary antibodies. Cell nuclei were counterstained with 
DAPI stain (Invitrogen). The tissues were imaged using a Carl Zeiss 2000 upright microscope. Quantification of 
surface expression levels of αv integrin and neuropilin-1 were performed using ImageJ (NIH) on representative 
sections from 11 different tumors. For each tumor specimen, at least six to nine randomly selected histological 
sections were chosen for quantification. For great auricular nerve staining, 6 distinct patient-derived specimens 
were used.
Flow Cytometry. Fluorescence-activated cell sorting (FACS) analyses of αv integrin and neuropilin-1 
expression were performed on OVCAR-8, HEI-193, and primary VS cells. Briefly, OVCAR-8 and HEI-193 cells 
were passaged in enzyme-free cell dissociation buffer and allowed to grow to 70% confluence prior to harvesting. 
The cells were trypsinized using enzyme-free cell dissociation solution and brought to single-cell suspension in 
1% BSA in 1 × PBS on ice. Approximately 0.5 x 106 cells were used for each condition. Primary antibody was 
added at 1 μg per 1 × 106 cells and incubated for one hour on ice. For integrin staining, mouse anti-human αvβ3 
antibody (BioLegend) was used. For neuropilin-1 staining, rabbit anti-NRP-1 (Novus Biologicals) was used. Cells 
were washed in PBS and incubated with fluorescently-tagged secondary antibodies (Alexa 488 goat anti-mouse 
and Alexa Fluor 647 goat anti-rabbit, Invitrogen, 1:1000) for one hour on ice. Cells were then washed in PBS 
twice, re-suspended in 1% BSA in PBS containing 1:2000 PI and analyzed on the BD LSRII flow cytometer. Six 
(6) independent replicates for each cell type were performed. For primary VS samples, cells from 4 different tum-
ors were pooled to ensure sufficient number of cells for flow cytometry. Data was analyzed in FlowJo (TreeStar 
Software).
Cellular uptake of nanoparticles. For cellular uptake experiments, both established cell lines (OVCAR-8 
human ovarian cancer cells or HEI-193 human vestibular schwannoma cells) were passaged in 1x enzyme-free 
cell-dissociation solution (EMD Millipore) 48 hours prior to allow regeneration of cell surface receptors, and 
grown in 24-well tissue culture plates on glass coverslips to 50–70% confluence. Primary VS cultures were grown 
as described previously. On the day of the experiment, nanoparticle formulations were prepared at indicated 
concentrations diluted in Opti-MEM. For visualization by immunofluorescence, siRNA molecules pre-labeled 
with Alexa Fluor 647 (Dharmacon) were used with either iRGD or scr control peptides. The cells were washed 
with PBS prior to incubation with nanoparticles. Freshly prepared nanoparticles were added to cells at 4 °C for 45 
minutes for assessment of cellular binding, or at 37 °C for 45 minutes if assessing internalization. The nanoparticle 
solutions were then gently aspirated and cells were rinsed in PBS twice, and processed for immunocytochemistry 
as described below. For flow cytometry, cells were washed with PBS, trypsinized using 0.025% trypsin to remove 
non-specifically bound nanoparticles, centrifuged to cell pellet at 300g for 5 minutes, and re-washed with 1% 
bovine serum albumin (BSA) in PBS at 4 °C two more times. The cells were finally re-suspended in 1% BSA 
in PBS with 1:2000 Propidium Iodide (PI; Invitrogen). The cells were analyzed for siRNA fluorescence gating 
PI-negative cells (BD LSR II instrument). For each experiment involving established cell lines, six (6) independent 
replicates with separately prepared nanoparticles and cell cultures were used and results were averaged. For each 
experiment involving primary VS cultures, four (4) distinct VS cultures from different patients were used and 
data was pooled.
To examine the specificity of receptor targeting, a competition assay with anti-αv integrin antibody was 
used to block the RGD-integrin interaction. HEI-193 cells were passaged in enzyme-free dissociation buffer 
and grown in 96-well plates to approximately 50–70% confluence for 48 hours, as described previously. On the 
day of the experiment, the cells were washed with PBS and pre-incubated with either αv-integrin antibody or 
isotype-control IgG antibody in Opti-MEM at indicated concentrations from 3 μg/mL to 50 μg/mL for 1 hr. 
Nanoparticles were then added to a final concentration of 100 nM siRNA and uptake was assessed as described. 
Results were reported from 6 independent replicates.
Assessment of cell viability. HEI-193 cells were plated in 96-well plates at 10,000 cells per well and 
allowed to grow to 50–70% confluence over 48 hours (N = 6 independent replicates). The cell culture medium 
was removed and siGFP complexed to either iRGD tandem peptides or scr control peptides were added to cells 
in Opti-MEM for 4 hours. After incubation with nanoparticles, 50 μl of the medium was removed and 50 μl of 
CellTiter-Glo reagent was added to each well. The plate was placed on an orbital plate shaker for 2 minutes at 
room temperature for cell lysis, and 80 μl of the cell lysate was transferred to a white-bottomed 96-well plate and 
luminescence was measured on the Tecan SpectroMax Gemini microplate reader (Molecular Devices).
Delivery of siRNA in cell culture. For TNFα silencing, iRGD or scr control nanoparticles loaded with 
siTNFα or siGFP were prepared independently, applied to HEI-193 cells or primary VS cultures in antibiotic-free 
Opti-MEM for 4 hours, followed by wash in PBS and exchange to serum-containing DMEM for an additional 2 
days prior to harvesting of either total RNA or cell-conditioned media. A commercial lipid transfection reagent, 
Lipofectamine RNAiMax (Invitrogen), was used as a positive control according to manufacturer’s instructions. 
For experiments involving Lipopolysaccharide (LPS) treatment, LPS stock solutions (Sigma-Aldrich) were pre-
pared in DMSO and frozen at −80 °C until further use. After treatment with various nanoparticle formulations 
and controls, LPS was added to cells at a final concentration 5 ng/ml for 18 hours at 37 °C, washed twice with PBS, 
and RNA or cell-conditioned media were collected as published previously by our laboratory11. For knockdown 
experiments in HEI-193 cells, six independent biological replicates were used. For experiments in primary VS 
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cultures, a total of 4–6 independently prepared nanoparticle formulations on cultures derived from different 
patients were used.
For RNAi inhibition of the NF-κB signaling pathway, nanoparticles were formulated with siRNAs 
against RELA or a control gene at a molar ratio of 10:1 (peptide to siRNA), per the protocol described above. 
Lipofectamine was used as a positive control. Primary VS cultures (N = 3 different tumors) were washed in PBS 
and incubated with various nanoparticle formulations in serum-free Opti-MEM for 4 hours at 37 °C, followed by 
exchange to serum-containing DMEM for an additional 2 days prior to harvesting of total RNA. The efficiency of 
gene knockdown was quantified using real-time quantitative PCR.
Quantitative RT-PCR. Quantitative real-time PCR (qRT-PCR) was performed with an Applied Biosystems 
Step One Plus Real-time PCR instrument using SYBR green PCR Master Mix (Qiagen). Total RNA was extracted 
with Trizol (Invitrogen) and used to synthesize the first-strand cDNA by using Oligo (dT)20 /random hexamer 
primer cocktails and SuperScript III reverse transcriptase (Invitrogen). For the PCR reaction, per each well of 
25 μl final volume, there was 12.5 μl 2X SYBR Green qPCR Master Mix (Applied Biosystems), 10.5 μl of ddH2O, 
1.0 μl of cDNA template (up to 100 ng of cDNA), and 1.0 μl (10 μM) of paired PCR primers. The thermal cycler 
profile was: Cycle 1: 95 °C for 10 min; Cycle 2: 40 cycles of 95 °C for 10 sec and 60 °C for 60 sec. The primer 
sequences were as follows: TaqMan Primers (Applied Biosystems) for NFKB1 (encoding p50 subunit of the NF-kB 
heterodimer, Hs01042010_m1), RELA (encoding p65 subunit of the NF-kB heterodimer, Hs01042010_m1), TNF 
(Hs01042010_m1), and GAPDH. Triplicate reactions for the gene of interest and the endogenous control were 
performed separately on the same cDNA samples, and each condition represents data from 6 independent repli-
cates for HEI-193 cells, and 4 to 6 distinct tumors. For data analysis, the melt curves were verified and only curves 
with one melting peak were used. GAPDH housekeeping gene was used as the endogenous control. CT values for 
genes were geometrically averaged and used for ΔΔCT calculations. Specifically, the relative fold change in gene 
expression was calculated as 2−Δ(ΔCT), where ΔCT = CT, target − CT, GAPDH, and ΔΔCT = ΔCT, treatment − ΔCT, control.
Measurement of TNFα secretions. Following nanoparticle treatment and LPS stimulation, the tumor 
cell secretions were collected in DMEM in triplicate by removing 100 μl of the conditioned media. All secretions 
were then snap frozen and stored at −80 °C until further use. The concentrations of TNFα protein from untreated 
tumor cells, cells treated with nanoparticles carrying TNFα siRNA or control siRNA, scr control nanoparti-
cles carrying TNFα siRNA, or lipofectamine positive controls were quantified by using human TNFα ELISA 
kit (R&D) following an established protocol11. A total of 4–6 independently prepared nanoparticles on unique 
primary VS cultures from different patients were used for each condition.
Statistical analyses. Unless otherwise indicated, one-way ANOVA was used (GraphPad) and P < 0.05 
was considered statistically significant. Tukey’s multiple comparison test was performed in ANOVA analysis. 
Two-tailed Student’s t test was used for pairwise comparisons.
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